

# Updates 2018: DSM-TACE in Lung-Ca, ICC and HCC

**DATE:** Saturday, 22 September 2018

**TIME:** 13:00 - 14:00

**ROOM:** 3.A

**VENUE:** CIRSE, Centro de Congressos de Lisboa

## CHAIRS

T. Vogl, Germany | R. Iezzi, Italy

## AGENDA:

13:00	Welcome and introduction	R. Iezzi, Rome/ IT
13:02	Regional chemoperfusion and embolisation of primary and secondary lung tumors: Present and Future	T. Vogl, Frankfurt a. M./ DE
13:14	TPCE with DSM: Systematic Analysis of Local and Systemic Effects in a Porcine Model	P. Isfort, Aachen/ DE
13:26	First survival data for patients with recurrent ICC treated with DSM-TACE after liver resection	C. Kuhl, Aachen/ DE
13:38	DSM-TACE for locally advanced HCC – experiences of Berlin and Rome	T. Albrecht, Berlin/ DE
13:50	Q&A - discussion	All, led by R. Iezzi

---

Satellite Symposium held in conjunction with CIRSE 2018 (Cardiovascular and Interventional Radiological Society of Europe). This symposium content is not an official part of the CIRSE scientific program, nor is it organized or endorsed by CIRSE.

# UNIVERSAL SHORT-TERM\* EMBOLIC AGENT IN DSM-TACE FOR LOCOREGIONAL TUMOR THERAPY.

\*half-life 35 min



- ⊙ excellent necrosis rates <sup>1,2</sup>
- ⊙ higher intra-tumor concentration <sup>3,4</sup>
- ⊙ combinable with many cytostatics <sup>5,6</sup>
- ⊙ unlimitedly repeatable DSM-TACE <sup>7,8</sup>
- ⊙ better tolerability <sup>9</sup>
- ⊙ easy handling without long preparation time <sup>10</sup>

DSM-TACE = degradable starch microspheres - transarterial chemoembolisation

1: Ziemann, C. et al.: Inhibition of tumor growth of colorectal liver metastases after transarterial chemoembolization using different chemoembolisats in rat model, presentation at Deutscher Krebskongress 2014. 2: Altomonte J. et al.: Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. *Hepatology*. 2008 Dec; 48(6):1864-73. 3: Pohlen, U. et al.: Increased carboplatin concentration in liver tumors through temporary flow retardation with starch microspheres (Spherex) and gelatin powder (Gelfoam): An experimental study in liver tumor-bearing rabbits, *Journal of Surgical Research* 92, 2000, 165-170. 4: Pohlen, U. et al.: Stealth liposomal 5-fluorouracil with or without degradable starch microspheres for hepatic arterial infusion in the treatment of liver metastases. An animal study in VX-2 liver tumor-bearing rabbits. *Anticancer Res*. 2004 May-Jun; 24(3a):1699-704. 5: Schicho, A. et al.: Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC). Results from a National Multi-Center Study on Safety and Efficacy. 2017 In: *Med. Sci. Monit*. 23, S. 796-800. DOI: 10.12659/MSM.902901. 6: Schicho A. et al.: Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. *Onco Targets Ther*. 2018 Jan 12;11:345-350. DOI: 10.2147/OTT.S147852 PMID: 9391811. 7: Vogl, T. et al.: Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: Local control and survival results, 2013, *European Journal of Radiology* 82, 258– 263. 8: Azizi, A. et al.: Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival. 2011, In: *Pancreas* 40 (8), S. 1271–1275. DOI: 10.1097/MPA.0b013e318220e5b9. 9: Schlee, V. et al.: Komplikationen und unerwünschte Wirkungen im Rahmen intraarterieller Tumortherapien. Inauguraldissertation, Medizinische Fakultät, Universität Bonn (Betreuer: Layer G), 1999. 10: Instructions for Use EmboCept® S, date of information: 30.06.2017.